» Articles » PMID: 28428275

Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas

Overview
Journal Cancer Res
Specialty Oncology
Date 2017 Apr 22
PMID 28428275
Citations 222
Authors
Affiliations
Soon will be listed here.
Abstract

The epithelial-to-mesenchymal transition (EMT) is a cell biological program that confers mesenchymal traits on carcinoma cells and drives their metastatic dissemination. It is unclear, however, whether the activation of EMT in carcinoma cells can change their susceptibility to immune attack. We demonstrate here that mammary tumor cells arising from more epithelial carcinoma cell lines expressed high levels of MHC-I, low levels of PD-L1, and contained within their stroma CD8 T cells and M1 (antitumor) macrophages. In contrast, tumors arising from more mesenchymal carcinoma cell lines exhibiting EMT markers expressed low levels of MHC-I, high levels of PD-L1, and contained within their stroma regulatory T cells, M2 (protumor) macrophages, and exhausted CD8 T cells. Moreover, the more mesenchymal carcinoma cells within a tumor retained the ability to protect their more epithelial counterparts from immune attack. Finally, epithelial tumors were more susceptible to elimination by immunotherapy than corresponding mesenchymal tumors. Our results identify immune cells and immunomodulatory markers that can be potentially targeted to enhance the susceptibility of immunosuppressive tumors to various therapeutic regimens. .

Citing Articles

Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.

Visal T, Bayraktar R, den Hollander P, Attathikhun M, Zhou T, Wang J Cancer Res. 2025; 85(5):894-911.

PMID: 39853244 PMC: 11873730. DOI: 10.1158/0008-5472.CAN-24-0400.


The metastatic cascade through the lens of therapeutic inhibition.

Miranda I, Jahan N, Shevde L Cell Rep Med. 2024; 6(1):101872.

PMID: 39706193 PMC: 11866422. DOI: 10.1016/j.xcrm.2024.101872.


Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.

Soupir A, Hayes M, Peak T, Ospina O, Chakiryan N, Berglund A Genome Biol. 2024; 25(1):308.

PMID: 39639369 PMC: 11622564. DOI: 10.1186/s13059-024-03435-z.


STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC.

Huang S, Qin X, Fu S, Hu J, Jiang Z, Hu M Adv Sci (Weinh). 2024; 12(1):e2405083.

PMID: 39527690 PMC: 11714167. DOI: 10.1002/advs.202405083.


The complexity of immune evasion mechanisms throughout the metastatic cascade.

Haynes N, Chadwick T, Parker B Nat Immunol. 2024; 25(10):1793-1808.

PMID: 39285252 DOI: 10.1038/s41590-024-01960-4.


References
1.
Crane C, Han S, Barry J, Ahn B, Lanier L, Parsa A . TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 2010; 12(1):7-13. PMC: 2940557. DOI: 10.1093/neuonc/nop009. View

2.
Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

3.
Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y . Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15(3):195-206. DOI: 10.1016/j.ccr.2009.01.023. View

4.
Viel S, Marcais A, Guimaraes F, Loftus R, Rabilloud J, Grau M . TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 2016; 9(415):ra19. DOI: 10.1126/scisignal.aad1884. View

5.
Kerkar S, Restifo N . Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012; 72(13):3125-30. PMC: 6327310. DOI: 10.1158/0008-5472.CAN-11-4094. View